SpringWorks Therapeutics Stock Closes at $26.10, Up 1.79%
June 29, 2023
🌥️Trending News
SPRINGWORKS ($NASDAQ:SWTX): SpringWorks Therapeutics Inc., a biopharmaceutical company focused on developing treatments and cures for rare diseases, saw its stock close at $26.10 yesterday, representing an increase of 1.79% from its previous close of $25.64. This increase came after investors examined the company’s financial ratios to make informed decisions. The company’s focus on rare diseases has made it an attractive investment opportunity in the biotechnology market. SpringWorks Therapeutics Inc. was founded by Pfizer and is led by seasoned executives with experience in both medical research and drug development. Its mission is to develop innovative treatments for rare genetic diseases with high unmet medical needs.
The company has a portfolio of potential therapies, including gene therapy, antibody-drug conjugates, small-molecule inhibitors, and other cutting-edge treatments. SpringWorks Therapeutics also has collaborations with leading research institutes and pharmaceutical companies. The company’s potential for growth, driven by its commitment to innovative research and drug development, has resulted in a growing investor base. The stock has had a strong performance over the past year and its future prospects show that SpringWorks Therapeutics Inc. is an attractive investment opportunity.
Analysis
At GoodWhale, we make it easy to analyze SPRINGWORKS THERAPEUTICS‘s fundamentals. According to our Risk Rating, SPRINGWORKS THERAPEUTICS is a medium risk investment in terms of financial and business aspects. Our analysis has also identified 2 risk warnings in SPRINGWORKS THERAPEUTICS’s balance sheet and cashflow statement. If you want a closer look at these risk warnings, simply register with us. We are always here to help you make informed decisions about your investments. More…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Springworks Therapeutics. More…
| Total Revenues | Net Income | Net Margin |
| 0 | -289.04 | -130.2% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Springworks Therapeutics. More…
| Operations | Investing | Financing |
| -174.69 | -143.42 | 338.59 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Springworks Therapeutics. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 569.2 | 62.27 | 8.11 |
Key Ratios Snapshot
Some of the financial key ratios for Springworks Therapeutics are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 0.0% | – | -132.4% |
| FCF Margin | ROE | ROA |
| -93.8% | -34.8% | -32.6% |
Peers
The company is focused on developing and commercializing therapies for the treatment of rare and underserved diseases. SpringWorks Therapeutics Inc’s competitors include Aadi Bioscience Inc, Avalo Therapeutics Inc, and Immunic Inc.
– Aadi Bioscience Inc ($NASDAQ:AADI)
Aadi Bioscience Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of small molecule drugs for the treatment of cancer and other diseases. The company’s lead product candidate is AB-101, a small molecule inhibitor of the PI3K/mTOR pathway, which is in Phase I clinical trials for the treatment of solid tumors. Aadi Bioscience Inc has a market cap of 317.87M as of 2022, a Return on Equity of -28.05%.
– Avalo Therapeutics Inc ($NASDAQ:AVTX)
Avalo Therapeutics Inc is a clinical stage biopharmaceutical company developing novel cancer therapies. The company’s market cap as of 2022 is 50.93M and its ROE is 729.23%. Avalo’s pipeline of products includes two clinical stage programs: AVL-292, a first-in-class, small molecule inhibitor of checkpoint kinase 1 (Chk1) for the treatment of solid tumors, and AVL-181, a first-in-class, small molecule inhibitor of checkpoint kinase 2 (Chk2) for the treatment of hematologic malignancies.
– Immunic Inc ($NASDAQ:IMUX)
Immunic, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing oral therapies for the treatment of immune-mediated diseases. Its pipeline includes IMU-838 that is in Phase II clinical trial for the treatment of plaque psoriasis and atopic dermatitis; and IMU-935, which is in Phase I clinical trial for the treatment of autoimmune diseases. The company was founded by Daniel M. Adelman, Michael J. Brenner and William T. Symonds on December 15, 2006 and is headquartered in New York, NY.
Summary
Investing in SpringWorks Therapeutics Inc. requires careful research and analysis of its financial ratios. As of close of business last night, the stock price was at $26.10, which was an increase of 1.79% from its previous closing price of $25.64. When analyzing the company, investors should consider its quick ratio, current ratio, debt-to-equity ratio, profit margin, and return on equity.
All these metrics give an insight into the company’s financial health and competitive position in the industry. Furthermore, investors should review the company’s past performance and future outlook to decide whether it is a good investment or not.
Related Posts
Recent Posts
Investing Everyone Can Do.
Investing shouldn’t be exclusive to a select few. We believe everyone should have the opportunity to grow their wealth. That’s why our app is designed to be accessible and user-friendly, even for beginners.
